These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3164750)

  • 41. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
    Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
    J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of combinations of deoxyguanosine and 8-aminoguanosine with 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on L1210 cell growth in culture.
    Sato A; Bacon PE; Schneller SW; Cory JG
    Biochem Pharmacol; 1984 Feb; 33(4):689-91. PubMed ID: 6704189
    [No Abstract]   [Full Text] [Related]  

  • 43. Phosphorylation of deoxyguanosine by B and T lymphocytes: evidence against selective trapping of deoxyguanosine by T lymphocytes in purine nucleoside phosphorylase deficiency.
    North ME; Newton CA; Webster AD
    Clin Exp Immunol; 1980 Dec; 42(3):523-9. PubMed ID: 6783354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
    Furman RR; Hoelzer D
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy.
    Herrström Sjöberg A; Wang L; Eriksson S
    Antimicrob Agents Chemother; 2001 Mar; 45(3):739-42. PubMed ID: 11181353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical and immunological abnormalities in purine nucleoside phosphorylase deficient mice.
    Arpaia E; Gu Y; Dalal I; Kelly S; Hershfield M; Roifman CM; Cohen A
    Adv Exp Med Biol; 2000; 486():41-5. PubMed ID: 11783524
    [No Abstract]   [Full Text] [Related]  

  • 47. Purine nucleoside phosphorylase deficiency: a molecular model for selective loss of T cell function.
    Ochs UH; Chen SH; Ochs HD; Osborne WR; Scott CR
    J Immunol; 1979 Jun; 122(6):2424-9. PubMed ID: 109531
    [No Abstract]   [Full Text] [Related]  

  • 48. Dipyridamole and 8-aminoguanosine inhibition of nucleoside metabolism in rat blood in vitro.
    Gilbertsen RB; Dong MK
    Adv Exp Med Biol; 1986; 195 Pt A():575-82. PubMed ID: 3088923
    [No Abstract]   [Full Text] [Related]  

  • 49. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase.
    Carson DA; Wasson DB; Lakow E; Kamatani N
    Proc Natl Acad Sci U S A; 1982 Jun; 79(12):3848-52. PubMed ID: 6808516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of 3H-thymidine incorporation by guanosine and deoxyguanosine in human lymphoid cells.
    van der Kraan PM; van Zandvoort PM; De Abreu RA; Bakkeren JA; van Laarhoven JP; de Bruyn CH
    Adv Exp Med Biol; 1986; 195 Pt A():547-51. PubMed ID: 3524141
    [No Abstract]   [Full Text] [Related]  

  • 51. Purine metabolism in human lymphocyte subpopulations. I. Differences in the effect of 2'-deoxyguanosine and guanosine on human normal E- and EAC-rosette forming cells.
    Sakura N; Usui T; Ito K
    Hiroshima J Med Sci; 1980 Dec; 29(4):195-201. PubMed ID: 7204106
    [No Abstract]   [Full Text] [Related]  

  • 52. 8'-aminoguanosine inclusion results in enhanced efflux of taurine in preconditioned ischemic myocardium.
    Kavianipour M; Ronquist G; Wikström G; Waldenström A
    J Cardiovasc Pharmacol; 2003 Feb; 41(2):240-8. PubMed ID: 12548085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of PNP inhibition on rat lymphoid cell populations.
    Barton RW; Osborne WR
    Adv Exp Med Biol; 1986; 195 Pt B():429-35. PubMed ID: 3020916
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
    Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
    Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Purine deoxynucleoside toxicity in nondividing human lymphoid cells.
    Kefford RF; Fox RM
    Cancer Res; 1982 Jan; 42(1):324-30. PubMed ID: 6976204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. O6-(alkyl/aralkyl)guanosine and 2'-deoxyguanosine derivatives: synthesis and ability to enhance chloroethylnitrosourea antitumor action.
    Mounetou E; Debiton E; Buchdahl C; Gardette D; Gramain JC; Maurizis JC; Veyre A; Madelmont JC
    J Med Chem; 1997 Aug; 40(18):2902-9. PubMed ID: 9288172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of salvage and phosphorylation in the immunostimulatory activity of C8-substituted guanine ribonucleosides.
    Goodman MG
    J Immunol; 1988 Oct; 141(7):2394-9. PubMed ID: 2459208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells.
    Traganos F; Ardelt B; Halko N; Bruno S; Darzynkiewicz Z
    Cancer Res; 1992 Nov; 52(22):6200-8. PubMed ID: 1330289
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Purine nucleoside phosphorylase (PNP)].
    Sakiyama T
    Nihon Rinsho; 1996 Dec; 54(12):3220-5. PubMed ID: 8976095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
    Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
    Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.